Pharma Marketing News Vol. 8, #7
Welcome to the August 2009 issue of Pharma Marketing News.
Waning Pharma Support of CME: The Plight of For-Profit MECCs
Recent headlines pulled from traditional media as well as from the blogo-sphere paint a bleak picture of the future of commercial support for continuing medical education (CME). Is the pharmaceutical industry getting out of the business of supporting CME? This article summaries Congressional testimony, ACCME data, and results of a reader survey on this topic.
Pharma Marketing News Vol. 8, #6
Welcome to the June/July 2009 issue of Pharma Marketing News.
How Should Pharma Engage in Social Networks?: Thoughts on Best Practices
Each pharmaceutical company should have its own guidelines for best practices in the social media space. To assist in that discussion, Pharma Marketing News hosted a survey to explores issue relating to pharma advertising and engagement in social networks. This article summarizes the results of that survey.
FDA Draft Guidance on Risk Communication: Reading the Tea Leaves
The recent FDA Draft Guidance for Industry, Presenting Risk Information in Prescription Drug and Medical Device Promotion guidance focuses almost exclusively on print and broadcast promotional ads. It is possible, however, to apply some of FDA's
Pharma Marketing News Vol. 8, #6
Welcome to the June/July 2009 issue of Pharma Marketing News.
Pharma Marketers Dive Deeper Into Social Media: The Good, the Bad, & the Ugly...
This article focuses in some detail on three interesting pharma social media initiatives: (1) Procter & Gamble's Asacol Community for Ulcerative Colitis Patients; (2) Novo Nordisk's Levemir-branded Race With Insulin Twitter account; and (3) UCB's sponsored epilepsy community on the PatientsLikeMe website.
Protection from Brand Infection: Marketers Must Take Control of Their Brands, Especially Online
In response to concerns about the growing range of threats to brand value and the sheer volume of brand hijacking incidents, the CMO Council set out to assess the challenges marketers face as stewards of their brands. The result is Protection from Brand Infection, a seminal authority leadership report that outlines the proliferating threat-scape that marketers face and reveals how marketers are struggling to understand and measure the impact brand intrusions have on their second most valuable asset, their customer.
Ramifications of FDA Regulatory Actions: Helping FDA Find a New Media Regulatory Pathway
Arnold Friede, counsel to the law firm McDermott Will & Emery LLP, and former Senior Counsel at Pfizer, believes that there is an opportunity now to make a strong and compelling argument for the adoption of rational regulatory policies by the FDA that address the unique features not only of sponsored links, but of other kinds of new communication tools, such as social media.
The New PhRMA Code and Beyond: Federal & State Laws are Eclipsing Self-Regulation
At a recent ExL Pharma conference industry leaders from pharma and the vendor community reviewed the impact on
